Monday 01 December 2025
Internal Reference Number: FOI_8953
Date Request Received: 08/10/2025 00:00:00
Date Request Replied To: 21/10/2025 00:00:00
This response was sent via: By Email
Request Summary: Lung Cancer
Request Category: Researcher
| Question Number 1: I am analysing the treatment of lung cancer and would greatly appreciate it if you could answer the following question: How many non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with: • ALK Inhibitors (Alectinib, Brigatinib, Ceritinib, Crizotinib, Lorlatinib) • Amivantamab Monotherapy • Atezolizumab monotherapy (any formulation) OR Atezolizumab monotherapy (infusion only) • Atezolizumab (any formulation) + Bevacizumab + Carboplatin + Paclitaxel • Atezolizumab monotherapy (subcutaneous injection only) • Dabrafenib + Trametinib • Docetaxel monotherapy or in combination with Carboplatin/Cisplatin • Durvalumab • Gemcitabine • Nintedanib + Docetaxel • Nivolumab • Osimertinib • Other EGFR Inhibitors (Afatinib, Erlotinib, Gefitinib, Dacomitinib, Mobocertinib) • Paclitaxel • Pembrolizumab Monotherapy • Pembrolizumab + Paclitaxel + Platinum (Carboplatin/Cisplatin) • Pembrolizumab + Pemetrexed + Platinum (Carboplatin/Cisplatin) • Pemetrexed + Platinum (Carboplatin/Cisplatin) • RET Inhibitors (Pralsetinib, Selpercatinib) • Sotorasib • Tepotinib • Vinorelbine monotherapy or in combination with Carboplatin/Cisplatin • Other active systemic anti-cancer therapy • Palliative care only • Amivantamab with carboplatin and pemetrexed • Cemiplimab with platinum-based chemotherapy • Adagrasib • Datopotamab deruxtecan • Amivantamab with lazertinib | |
| Answer To Question 1: ALK Inhibitors (Alectinib, Brigatinib, Ceritinib, Crizotinib, Lorlatinib) 12 • Amivantamab Monotherapy 0 • Atezolizumab monotherapy (any formulation) OR Atezolizumab monotherapy (infusion only) <5 • Atezolizumab (any formulation) + Bevacizumab + Carboplatin + Paclitaxel <5 • Atezolizumab monotherapy (subcutaneous injection only) <5 • Dabrafenib + Trametinib <5 • Docetaxel monotherapy or in combination with Carboplatin/Cisplatin 0 • Durvalumab 5 • Gemcitabine 0 • Nintedanib + Docetaxel <5 • Nivolumab 0 • Osimertinib 17 • Other EGFR Inhibitors (Afatinib, Erlotinib, Gefitinib, Dacomitinib, Mobocertinib) <5 • Paclitaxel 0 • Pembrolizumab Monotherapy 6 • Pembrolizumab + Paclitaxel + Platinum (Carboplatin/Cisplatin) <5 • Pembrolizumab + Pemetrexed + Platinum (Carboplatin/Cisplatin) 17 • Pemetrexed + Platinum (Carboplatin/Cisplatin) <5 • RET Inhibitors (Pralsetinib, Selpercatinib) 0 • Sotorasib <5 • Tepotinib <5 • Vinorelbine monotherapy or in combination with Carboplatin/Cisplatin <5 • Other active systemic anti-cancer therapy <5 • Palliative care only unable to answer • Amivantamab with carboplatin and pemetrexed 0 • Cemiplimab with platinum-based chemotherapy 0 • Adagrasib 0 • Datopotamab deruxtecan 0 • Amivantamab with Lazertinib 0 | |
| Question Number 2: . Does your trust participate in any clinical trials for Non-Small Cell Lung Cancer? If so, please provide the name of each trial, and the number of patients taking part. | |
| Answer To Question 2: The Trust currently do not have any clinical trials for lung cancer that are open to recruitment. However, we have expressed interest to sponsors in a few studies for which we are yet to receive feedback. Previously, we have participated in the ET Trial and TACTIC. | |
| To return to the list of all the FOI requests please click here |
Our staff at Salisbury District Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
